Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs

Program Description

Duchenne muscular dystrophy (DMD) is an X-linked recessive disease characterized by muscular weakness in early childhood that progresses to multisystem complications and premature death. The clinical and economic burden on patients and their caregivers is immense. As burden of disease increases, so does the clinical burden and impacts on quality of life (QOL). Treatment of DMD is focused on maintaining the patient’s QOL, delaying disease progression, treating complications, and extending survival. Pharmacists have key roles in the management of DMD to support patients and the multidisciplinary team in adapting treatment to the individual patient and their stage of clinical development. This podcast will outline the role of specialty pharmacists from initial patient consultations through treatment selection and follow-up throughout the patient’s care journey to monitor the efficacy and safety of medications, manage adverse effects, and ensure appropriate regular testing and tracking of patient progress.

Target audience: Health-system, managed care, retail, and specialty pharmacists

Type of activity: Knowledge
Release date: December 22, 2022
Expiration date: December 22, 2023

Time to complete activity: 0.75 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life
• List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Amanda Hickman, PharmD, MPH, MSCS

Moderator

Jessica L. Kerr, PharmD, CDCES

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms